2010 Annual Meeting Abstracts
Back to Program
Oral Pterostilbene Inhibits Pancreatic Cancer Growth in a Mouse Model
*Patrick Mannal, David McFadden
University of Vermont, Burlington, VT
Objective: The current study is designed to evaluate the ability of orally administered Pterostilbene to inhibit pancreatic cancer tumor growth in vivo.
Design: Pilot study, animal xenograft model.
Setting: Animal care facility; tertiary care center with surgical oncology specialists.
Participants: 40 Nu/Nu (athymic) mice.
Interventions: Pancreatic cancer cells (MIA PaCa-2) were cultured using standard techniques. 40 Nu/Nu (athymic) mice were inoculated with 6 x 106 MIA pancreatic cancer cells in the right flank. Once the tumor volumes reached 150mm³, oral Pterostilbene in its vehicle DMSO was administered in concentrations of 100µg/kg/day, 500µg/kg/day, or 1mg/kg/day for 8 weeks. DMSO plus water was used as a control. Tumor volumes and animal weights were recorded three times weekly.
Main Outcome Measures: Rate of tumor growth in treatment vs. control groups after initiation of oral Pterostilbene administration.
Results: Using an exponential tumor growth model, unique tumor growth rate parameters for each of the 4 animal groups were formulated. Growth rate parameters were as follows: Control (0.0522), 100µg/kg/day (0.0260), 500µg/kg/day (0.0264), and 1mg/kg/day (0.0371). Based upon 95% confidence intervals, the 100µg/kg/day and 500µg/kg/day groups had statistically significant tumor growth inhibition versus controls. 100% of animals in the treatment arms survived, whereas the control group had a 66% survival rate. Histologically the tumors were similar across treatment groups, showing areas of central necrosis and perineural invasion typical of pancreatic adenocarcinoma.
Conclusions: This pilot study is the first to demonstrate oral Pterostilbene’s in vivo effectiveness against pancreatic cancer. While confirming our previous in vitro findings of Pterostilbene’s anti-cancer capabilities, these results justify larger in vivo studies and human trials to clarify effective dosing and treatment duration for this novel anti-cancer compound.
Back to Program